SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

SBIR TOPIC 096:Novel Biodegradable Stents for Neonatal Aortic Coarctation
Award last edited on: 10/8/2019

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$3,395,493
Award Phase
2
Solicitation Topic Code
NHLBI
Principal Investigator
Rashida S Ferebee

Company Information

Lyra Therapeutics Inc (AKA: WMR Biomedical~480 Biomedical Inc~Arsenal Medical)

480 Arsenal Street Suite 4
Watertown, MA 02472
   (617) 393-4600
   contactus@lyratx.com
   www.lyratherapeutics.com
Location: Single
Congr. District: 05
County: Middlesex

Phase I

Contract Number: 268201600041C-0-0-0
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2016
Phase I Amount
$397,952
Aortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation in children especially in neonates Neonates require small delivery systems for relatively large nominal diameter implants which is technically challenging No commercial alternatives are available for off label medical use There is a considerable unmet need for a purpose built absorbable scaffold stent for neonatal aortic coarctation

Phase II

Contract Number: 268201600041C-2-0-0
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2018
Phase II Amount
$2,997,541
Aortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation in children especially in neonates Neonates require small delivery systems for relatively large nominal diameter implants which is technically challenging No commercial alternatives are available for off label medical use There is a considerable unmet need for a purpose built absorbable scaffold stent for neonatal aortic coarctation